BiotechTube
AceLink Therapeutics

AceLink Therapeutics

San Mateo, United States· Est.
acelinktherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $106M

Overview

AceLink Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Newark, California, with a significant operational presence in Shanghai, China. The company's core strategy is targeting glycolipid biology with small molecule inhibitors and activators to treat rare genetic diseases, with three lead programs in Phase 2 and preclinical development. Its most advanced asset, AL01211, is a non-brain penetrant GCS inhibitor in Phase 2 for Fabry disease and Type I Gaucher disease, positioning it in a competitive but high-need therapeutic area.

Lysosomal Storage DisordersRare Genetic DiseasesRenal Diseases

Technology Platform

Modulation of glycolipid metabolism through Glucosylceramide Synthase (GCS) inhibition (both brain-penetrant and non-penetrant) and NRF2 activation.

Funding History

2
Total raised:$106M
Series B$59M
Series A$47M

Opportunities

The successful Phase 2 data for AL01211 in Fabry disease creates a near-term opportunity for partnership or further funding.
The brain-penetrant AL0804 addresses severe, untreated neurological disorders with high unmet need, offering potential for breakthrough therapy designation.
The ADPKD program opens access to a significantly larger multi-billion dollar market.

Risk Factors

Key risks include clinical trial failure, particularly in the ongoing and future studies for its lead asset.
The company faces intense competition in the substrate reduction therapy space for Fabry and Gaucher diseases.
As a private, pre-revenue firm, it is also exposed to financial risk and dependence on the capital markets for funding.

Competitive Landscape

In Fabry and Gaucher disease, AceLink competes with established enzyme replacement therapies and other oral substrate reduction therapies from companies like Sanofi (eliglustat) and Amicus (miglustat, newer candidates). For its neuronopathic programs, competition is less about marketed drugs and more about other pre-clinical and clinical efforts targeting these ultra-rare diseases. In ADPKD, it would compete with Otsuka's tolvaptan and other novel mechanisms in development.

More companies in Small Molecule Drugs →More companies in United States →